Sector: Technology | Industry: Software |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 11 Huron Dr Ste 200 NATICK MA 01760 |
Tel: | N/A |
Website: | https://www.allurion.com/en |
IR: | See website |
Key People | ||
Omar Syed Ishrak Lead Independent Co-Chairman of the Board | Krishna K. Gupta Independent Co-Chairman of the Board | Shantanu Gaur Chief Executive Officer, Director |
Christopher Geberth Chief Financial Officer | Ram Chuttani Chief Medical Officer |
Business Overview |
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform and health tracker devices. Its health tracker devices include Allurion Connected Scale and Allurion Health Tracker. Allurion Connected Scale offers a complete weight tracking experience, allowing users to monitor their weight, body mass index (BMI) and body composition. Allurion Health Tracker tracks steps, exercise and sleep. Allurion Virtual Care Suite is available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan, which includes gastric balloon, surgical and medical or nutritional. Its Allurion Programme is offered in six months, 12 months and 12-18 months program. |
Financial Overview |
For the fiscal year ended 31 December 2023, Allurion Technologies Inc revenues decreased 17% to $53.5M. Net loss applicable to common stockholders increased from $40.7M to $82.3M. Revenues reflect All other countries segment decrease of 24% to $35.1M, Chile segment decrease of 46% to $2.7M, Spain segment decrease of 33% to $4.6M. Higher net loss reflects Software segment loss increase from $32M to $79.1M. |